Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Celldex: I View the Recent Data on Rindopepimut as Encouraging (CLDX, Hold, $22.52) (Subscribers Only)

Report Overview
Celldex released interim data on the ReACT trial of rindopepimut in recurrent glioblastoma at the Society for Neuro-Oncology (SNO)…
Read more…

Celldex Stay Tuned for Monday’s Conference Call on Rindopepimut (CLDX, Hold, $28.31)

Investment Significance of Upcoming Conference Call
Celldex (CLDX) has raised expectations for positive results for rindopepimut in recurrent glioblastoma. It will…
Read more…

ImmunoCellular Thoughts on Potential Outcomes for the Phase II Trial of ICT-107 in Newly Diagnosed Glioblastoma (IMUC, $2.31) (Subscribers Only)

Investment Viewpoint
ImmunoCellular has extremely important data upcoming on the phase II trial of ICT-107 in newly diagnosed glioblastoma; topline results…
Read more…

Celldex (CLDX, $23.06): Previewing the Imminent Data Release on Rindopepimut

Note: Comprehensive reports are now available to paid subscribers and can be found in the Reports section.

Investment Background and Thesis
This post is the…
Read more…

Celldex Initiation Report: Pipeline Promise Has Been Embraced by Wall Street (CLDX, Hold, $22.79)

Review of Amazing and Volatile Stock Price Performance
From the closing price on December 30, 2011 through October 1, 2013 Celldex’s…
Read more…